{"id":"lantus-amaryl","safety":{"commonSideEffects":[{"rate":"5-30","effect":"Hypoglycemia"},{"rate":"2-5","effect":"Weight gain"},{"rate":"1-5","effect":"Injection site reactions (Lantus)"},{"rate":"1-3","effect":"Headache (Amaryl)"},{"rate":"1-2","effect":"Dizziness (Amaryl)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Lantus (insulin glargine) is a recombinant human insulin analog with a prolonged duration of action (up to 24 hours), providing steady basal insulin coverage. Amaryl (glimepiride) is a short-acting insulin secretagogue that binds to ATP-sensitive potassium channels on beta cells, triggering insulin secretion primarily during and after meals. Together, they provide both basal and prandial insulin coverage for glycemic control.","oneSentence":"Lantus is a long-acting basal insulin that lowers blood glucose by promoting glucose uptake and utilization in peripheral tissues and inhibiting hepatic glucose production, while Amaryl is a meglitinide that stimulates pancreatic beta cells to release insulin in response to meals.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:51:40.751Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"},{"name":"Type 1 diabetes mellitus (Lantus)"}]},"trialDetails":[{"nctId":"NCT02036515","phase":"PHASE3","title":"Safety and Efficacy of Ertugliflozin in the Treatment of Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin and Sitagliptin (MK-8835-006; VERTIS SITA2)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-03-12","conditions":"Type 2 Diabetes Mellitus","enrollment":464},{"nctId":"NCT02099110","phase":"PHASE3","title":"Ertugliflozin and Sitagliptin Co-administration Factorial Study (VERTIS FACTORAL, MK-8835-005)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-04-22","conditions":"Type 2 Diabetes Mellitus","enrollment":1233},{"nctId":"NCT01755156","phase":"PHASE3","title":"A Study to Evaluate the Safety, Tolerability, and Efficacy of the Addition of Omarigliptin (MK-3102) to Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Therapy (MK-3102-024)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-01-11","conditions":"Type 2 Diabetes Mellitus","enrollment":402},{"nctId":"NCT02033889","phase":"PHASE3","title":"A Study To Evaluate The Efficacy And Safety Of Ertugliflozin In Participants With Type 2 Diabetes Mellitus And Inadequate Glycemic Control On Metformin Monotherapy (MK-8835-007).","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-12-13","conditions":"Type 2 Diabetes Mellitus","enrollment":621},{"nctId":"NCT01682759","phase":"PHASE3","title":"A Study of the Safety and Efficacy of Omarigliptin (MK-3102) Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-016)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-09-10","conditions":"Type 2 Diabetes Mellitus","enrollment":751},{"nctId":"NCT00000620","phase":"PHASE3","title":"Action to Control Cardiovascular Risk in Diabetes (ACCORD)","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"1999-09","conditions":"Atherosclerosis, Cardiovascular Diseases, Hypercholesterolemia","enrollment":10251},{"nctId":"NCT00506194","phase":"NA","title":"Short-Term Intensive Insulin Therapy Induction of Long-term Glycemic Control","status":"COMPLETED","sponsor":"Taipei Veterans General Hospital, Taiwan","startDate":"2005-10","conditions":"Type 2 Diabetes","enrollment":60},{"nctId":"NCT00474838","phase":"PHASE4","title":"Study To Evaluate Beta Cell Function and Glycemic Outcome by Intensive Insulin Therapy","status":"COMPLETED","sponsor":"Kyunghee University Medical Center","startDate":"2007-04","conditions":"Type 2 Diabetes Mellitus, Pancreatic Beta Cell Function, Glucotoxicity","enrollment":112},{"nctId":"NCT00913367","phase":"PHASE4","title":"Efficacy/Safety Study of Amaryl®M 1/500 mg Twice Daily Versus Amaryl® 4 mg Both in Combination With Lantus® in Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Handok Inc.","startDate":"2009-05","conditions":"Type 2 Diabetes Mellitus","enrollment":110},{"nctId":"NCT00978263","phase":"NA","title":"Comparison of Glargine and Oral Antidiabetic Drugs (OADs) in Newly Diagnosed Type 2 Diabetes","status":"COMPLETED","sponsor":"Chongqing Medical University","startDate":"2009-02","conditions":"Diabetes","enrollment":47},{"nctId":"NCT00151697","phase":"PHASE3","title":"LANN-study: Lantus, Amaryl, Novorapid, Novomix Study","status":"COMPLETED","sponsor":"Rijnstate Hospital","startDate":"2005-05","conditions":"Diabetes Mellitus Type II","enrollment":150},{"nctId":"NCT00642915","phase":"PHASE4","title":"Insulin Glargine Benefits in Japanese Pts Outside of Japan (US or Brazil)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2003-06","conditions":"Diabetes Mellitus","enrollment":100}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["insulin glargine,glimepiride"],"phase":"marketed","status":"active","brandName":"Lantus, Amaryl","genericName":"Lantus, Amaryl","companyName":"Sanofi","companyId":"sanofi","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Lantus is a long-acting basal insulin that lowers blood glucose by promoting glucose uptake and utilization in peripheral tissues and inhibiting hepatic glucose production, while Amaryl is a meglitinide that stimulates pancreatic beta cells to release insulin in response to meals. Used for Type 2 diabetes mellitus, Type 1 diabetes mellitus (Lantus).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}